MIAMI / Sep 12, 2024 / Business Wire / Ontrak, Inc. (NASDAQ: OTRK), a leading AI-powered and technology-enabled behavioral healthcare company, announced significant findings from the first two-quarters of data collected through its implementation of the Recovering Quality of Life (ReQoL) measure. This patient-reported outcome measure (PROM) assesses the quality of life for individuals with various mental health conditions.
The ReQoL assessment, now a standard component of Ontrak's clinical model, has provided valuable insights into factors impacting mental health across diverse populations. ReQoL assessments are intended to evaluate the impact of mental health conditions, psychological interventions, and healthcare interventions on members’ lives because they focus on understanding the person over the diagnosis, consistent with modern recovery-oriented strategies. Integrating this tool in Ontrak's WholeHealth+ program emphasizes the commitment to measurement feedback in continually improving mental health care and outcomes.
Key Findings:
Dr. Judith Feld, MD, MPH, MMM, Chief Medical Officer at Ontrak Health, commented on the findings: "The ReQoL data results provide us with more nuanced insights into the mental health challenges faced by our members. The ReQoL measure has proven to be a powerful tool for uncovering hidden struggles and tracking clinical progress. Utilizing the ReQoL in our clinical programs has significantly improved the effectiveness of our tech-enabled personalized interventions.”
About Ontrak Health
Ontrak Health (Nasdaq: OTRK) is a leading AI and technology-enabled behavioral healthcare company whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates, and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder, and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socioeconomic, medical, and health system barriers that exacerbate the severity of their comorbid illnesses. The company's integrated intervention platform uses AI, predictive analytics, and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.
Last Trade: | US$1.44 |
Daily Change: | -0.02 -1.37 |
Daily Volume: | 17,045 |
Market Cap: | US$6.080M |
November 13, 2024 November 06, 2024 September 11, 2024 September 05, 2024 August 29, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB